ClinicalTrials.gg
RecruitingNCT07418177Updated Nov 13, 2026

Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD

A Phase 1/2 interventional study of hiPSC-RPEs in AMD - Age-Related Macular Degeneration, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 19, 2026Now RecruitingSite recruiting status changed+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
79th of 91
12 · median 62
Started
2025
with 14 others
Phase 1/2
18 of 107
8 open now
Primary completion
2028-12
later than 37 of 42 live
Registered
99th of 107
by date

Among the 107 studies in Macular Degeneration with a site in China, this one is the 79th largest by planned enrollment of the 91 interventional ones that give a count, is one of 15 that started in 2025, is one of 18 in phase 1/2, reaches primary completion later than 37 of the 42 other live ones, and was the 99th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 107 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial Cells (hiPSC-RPEs) Subretinal Transplantation in Adanced (Late-Stage) Age-Related Macular Degeneration(AMD) Patients.

03

Conditions studied

  • AMD - Age-Related Macular Degeneration

Keywords

  • Age-Related Macular Degeneration
  • AMD
  • hiPSC-RPEs
  • geographic atrophy
  • wet AMD
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1)Age ≥50 years and ≤85 years, regardless of gender.
  • (2)Patients with atrophic AMD in the macular area (geographic atrophy >250μm, involving the foveal center); or inactive neovascular AMD patients who have undergone treatment for wet AMD or have naturally converted to non-exudative AMD (referring to patients with fibrovascular scar formation, who are unresponsive to anti-VEGF treatment, and have no macular edema on OCT and/or no fluorescein leakage on FFA), with a scar diameter not exceeding 6 PD.
  • (3)Best-corrected visual acuity (BCVA) of the study eye ≥5 letters and ≤34 letters (using the ETDRS visual acuity chart).
  • (4)If both eyes meet the criteria, the more severely affected eye will be selected; if the severity is the same in both eyes, the right eye will be designated as the study eye.
  • (5)The patient or their legal representative has signed a written form.

Exclusion criteria

Exclusion Criteria:

  • Ocular Diseases:
  • (1)Vitreous hemorrhage in the study eye within 2 months prior to screening.
  • (2)Presence of a scar or fibrosis involving the fovea in the study eye, or a peripheral scar area greater than 6 PD, indicating severe irreversible visual loss.
  • (3)Presence of pseudoexfoliation syndrome, central retinal vein occlusion, intraocular hemorrhage causing visual loss, rhegmatogenous retinal detachment, macular hole, or active choroidal neovascularization in the study eye.
  • (4)Afferent pupillary defect (APD) in the study eye.
  • (5)Significant media opacity in the study eye (excluding lens opacities) that may interfere with visual function assessment or fundus examination.
  • (6)Acute infectious inflammation in either eye during the screening period.
  • (7)Patients with intraocular pressure higher than 25 mmHg despite medical treatment.
  • (8)Monocular blind patients.

Ocular Treatments:

  • (9)The study eye has undergone focal/grid laser photocoagulation within 3 months prior to screening.
  • (10)The study eye has undergone any intraocular surgery within 3 months prior to screening.
  • (11) Any eye has received anti-angiogenic therapy (including any anti-VEGF agents, e.g., Aflibercept [Eylea®], Ranibizumab [Lucentis®], Bevacizumab [Avastin®]) within 1 month prior to screening; or has undergone cataract surgery within 1 month prior to screening with unstable postoperative ocular conditions.

Systemic Diseases, Treatments, and Other Conditions:

  • (12)Patients with an allergic reaction or history of allergy to sodium fluorescein and indocyanine green, a history of allergy to protein products used for treatment or diagnosis, and patients with allergies to two or more drugs and/or non-drug factors, or those currently suffering from allergic diseases.
  • (13)Patients with uncontrolled diabetes (fasting blood glucose ≥7.0 mmol/L or 2-hour postprandial blood glucose ≥11.1 mmol/L).
  • (14)Patients with a history of surgical procedures within 1 month prior to screening, or those with unhealed wounds, ulcers, fractures, etc.
  • (15)Patients with uncontrolled hypertension (defined as a single measurement of systolic blood pressure >180 mmHg, two consecutive measurements of systolic blood pressure >160 mmHg, or diastolic blood pressure >100 mmHg despite optimal treatment).
  • (16)Patients with a history of myocardial infarction within 6 months prior to enrollment.
  • (17)Patients with active disseminated intravascular coagulation or a significant tendency to bleed; patients who have used anticoagulant or antiplatelet aggregation drugs within 14 days prior to screening, except for aspirin/nonsteroidal anti-inflammatory drugs.
  • (18) Presence of any uncontrolled systemic clinical conditions, such as interstitial pneumonia, severe psychiatric, neurological, cardiovascular, or respiratory diseases, malignant tumors, Parkinson's disease, Alzheimer's disease, or other severe systemic disorders.
  • (19)Women of childbearing age with a positive pregnancy test during the screening period. Women who wish to breastfeed during the study period, and all patients of childbearing age (male and female) who do not agree to take effective measures (such as intrauterine devices, oral contraceptives, or condoms) throughout the study period and for 30 days after the end of the visit period.
  • (20)Patients who have participated in or are currently participating in other clinical studies within 30 days prior to screening.
  • (21) \<100 g/L, ≤100×10\^9/L, \<1.0×10\^9/L, /AST >1.5× (ULN), creatinine >1.3 mg/dL.
  • (22)Subjects with any finding in virological tests (, , and TPPA).
  • (23)Patients deemed unsuitable for inclusion by the investigator, or other medical conditions that limit the subject's compliance, safety, or affect the results of the trial results.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    HiO-630 Dose-Escalation Cohorts

    Participants will receive a single subretinal injection of HiO-630. Three ascending dose cohorts are included: 200,000 cells/eye (low dose), 400,000 cells/eye (mid dose), and 600,000 cells/eye (high dose). Enrollment into the next higher-dose cohort will commence upon completion of safety assessment for the preceding cohort.

    Biological: hiPSC-RPEs

Interventions

  • BiologicalhiPSC-RPEs

    hiPSC-RPEs transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure

    Also known as: HiO-630

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Treatment-Related Adverse Events

    Any adverse reactions/adverse events (AEs) related to hiPSC-RPEs treatment occurring within 2 years after the completion of hiPSC-RPEs administration in all subjects, and their severity (graded according to CTCAE criteria).

    Time frame: Within 2 years after administration

Secondary outcomes

  1. Assessment of visual acuity using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart.

    Best-corrected visual acuity (BCVA) of the study eye and fellow eye will be measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. Subjects wearing soft contact lenses shall remove the lenses and wait for 30 minutes prior to the examination. Under standard illumination conditions, subjects wear their best refractive correction, occlude the non-tested eye, and identify letters line-by-line at a distance of 4 meters. One point is awarded for each correctly identified letter. If ≥20 letters are correctly identified at 4 meters, the ETDRS score equals the number of letters correctly read at 4 m plus 30. If fewer than 20 letters are correctly identified, testing of the first 6 lines will be performed at 1 meter, and the final score is the sum of correctly identified letters obtained at 4 m and 1 m.

    Time frame: From enrollment to the end of study at 12 months

  2. Change-from-baseline in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) total score

    NEI-VFQ-25 questionnaire will be used to assess trial participants. Uniformly trained investigators will administer each item following standardized instructions. Participants will respond based on their actual visual function and daily life experience, and investigators will record responses truthfully. Domain scores and the composite score will be calculated according to the NEI-VFQ-25 scoring rules. All scores are transformed to a scale ranging from 0 to 100, with higher scores indicating better visual function and visual-related quality of life.

    Time frame: From enrollment to the end of study at 12 months

Other outcomes

  1. Change-from-baseline in geographic atrophy lesion area measured by fundus autofluorescence (FAF) at 1 year post-treatment

    Geographic atrophy lesion area will be assessed using fundus autofluorescence (FAF) imaging. Lesion area is measured in square millimeters (mm²).

    Time frame: From enrollment to the end of study at 12 months

  2. Change-from-baseline in macular and graft-site retinal structure assessed by optical coherence tomography (OCT) at 1 year post-treatment

    OCT examination will be performed on the study eye to measure the central macular retinal thickness. Cross-sectional images of the macular region and cell graft area will be acquired to evaluate the integrity of retinal layers, RPE and outer retinal structure, as well as abnormal findings such as intraretinal or subretinal fluid.

    Time frame: From enrollment to the end of study at 12 months

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital with Nanjing Medical University
    Nanjing, Jiangsu 210029, China
    Recruiting
    • Yue Wang · Contact+86 13405818362
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2028, 38 months after the start.

Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 38 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: start Feb 2026 → Oct 2025 and primary completion Jun 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Feb 18, 2026
StartActual
Oct 14, 2025was Feb 2026
Primary completionEst.
Dec 31, 2028was Jun 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 19, 2026
Sites
The First Affiliated Hospital with Nanjing Medical University is now Recruiting
Oct 19, 2026
Start date
Feb 10, 2026→Oct 14, 2025 (actual)
Oct 19, 2026
Primary completion
Jun 1, 2028→Dec 31, 2028
Oct 19, 2026
Enrollment
9→12
Oct 19, 2026
Eligibility
Maximum age 80 Years→85 Years; 2 inclusion criteria edited; 9 exclusion criteria edited, 1 added
What changed in the criteria
Inclusion criteria
  • Edited(1)Age ≥50 years and ≤8085 years, regardless of gender.
  • Edited(2)Patients with atrophic AMD in the macular area (geographic atrophy >250μm, involving the foveal center); or stable non-exudativeinactive neovascular AMD patients who have undergone treatment for wet AMD or have naturally converted to non-exudative AMD (referring to patients with fibrovascular scar formation, who are unresponsive to anti-VEGF treatment, and have no macular edema on OCT and/or no fluorescein leakage on FFA), with a scar diameter not exceeding 6 PD.
Exclusion criteria
  • Edited(2)Presence of a scar, fibrosis, or atrophyfibrosis involving the fovea in the study eye, or a peripheral scar area greater than 6 PD, indicating severe irreversible visual loss.
  • Edited(3)Presence of pseudoexfoliation syndrome, central retinal vein occlusion, intraocular hemorrhage causing visual loss, rhegmatogenous retinal detachment, macular hole, or active choroidal neovascularization due to any cause in the study eye.
  • Edited(4)Presence of aAfferent pupillary block defect (APD) in the study eye.
  • Edited(5)Significant media opacity in the study eye (excluding lens opacities) that may interfere with visual function assessment or fundus examination.
  • ChangedBefore (10)The study eye has undergone the following intraocular surgeries or laser treatments within 3 months prior to screening, such as macular translocation, cataract surgery, glaucoma filtration surgery, verteporfin photodynamic therapy, transpupillary thermotherapy, foveal laser photocoagulation, vitrectomy, optic nerve decompression, or optic nerve sheath decompression.Now (10)The study eye has undergone any intraocular surgery within 3 months prior to screening.
  • Edited(11) Any eye has received anti-angiogenic drug treatmenttherapy (including any anti-VEGF drugs) within 3 months prior to screening (agents, e.g., Aflibercept [Eylea®], Ranibizumab [Lucentis®], Bevacizumab [Avastin®]) within 1 month prior to screening; or has undergone cataract surgery within 1 month prior to screening with unstable postoperative ocular conditions.
  • Edited(18)Patients with Presence of any uncontrollableuncontrolled systemic clinical issues (conditions, such as interstitial pneumonia, severe psychiatric, neurological, cardiovascular, or respiratory diseases, malignant tumors, Parkinson's disease, Alzheimer's disease, andor other severe systemic diseases)disorders.
  • Edited(21)Hemoglobin <100 g/L, platelets ≤100×10910\^9/L, neutrophil count <1.0×10910\^9/L, ALT/AST >1.5×upper limit of normal (ULN), creatinine >1.3 mg/dL.
  • Added(22)Subjects with any clinically significant finding in virological tests (HIV, HBV, HCV and TPPA).
  • Edited(2223)Patients deemed unsuitable for inclusion by the investigator, or other medical conditions that limit the subject's compliance, safety, or affect the results of the study trialtrial results.
Oct 19, 2026
Interventions
Added Biological: hiPSC-RPEs; removed Biological: HiPSC-RPE cells·Drug: Erlotinib (150 mg daily)·Drug: Prednisone. Arms added: HiO-630 Dose-Escalation Cohorts; arms removed: HiPSC-RPE cells
Oct 19, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Number of subjects with adverse eventsNow Incidence and Severity of Treatment-Related Adverse EventsTime frame: Two years following transplantation → Within 2 years after administration
Oct 19, 2026
Secondary outcomes
1 edited, 1 time frame changed, 2 added, 1 description edited
What changed in the outcomes
  • ChangedBefore Assessment of visual function changes-microperimetryNow Change-from-baseline in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) total scoreTime frame: From enrollment to the end of visiting at 2 years → From enrollment to the end of study at 12 months
  • Time frameAssessment of visual acuity using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart.From enrollment to the end of visiting at 2 years → From enrollment to the end of study at 12 months
  • DescriptionAssessment of visual acuity using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart.: how it is measured was reworded
  • Addedother outcomeChange-from-baseline in geographic atrophy lesion area measured by fundus autofluorescence (FAF) at 1 year post-treatmentTime frame: From enrollment to the end of study at 12 months
  • Addedother outcomeChange-from-baseline in macular and graft-site retinal structure assessed by optical coherence tomography (OCT) at 1 year post-treatmentTime frame: From enrollment to the end of study at 12 months
Oct 19, 2026
Title
Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-Stagestage) AMD
Oct 19, 2026
Show all 2 updates
  1. Nov 13, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 19, 2026
    Not yet recruiting→Recruiting
    The First Affiliated Hospital with Nanjing Medical University is now Recruiting
    Start date Feb 10, 2026→Oct 14, 2025 (now actual)
    Primary completion Jun 1, 2028→Dec 31, 2028
    Enrollment 9→12
    Eligibility Maximum age 80 Years→85 Years; 2 inclusion criteria edited; 9 exclusion criteria edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • Edited(1)Age ≥50 years and ≤8085 years, regardless of gender.
    • Edited(2)Patients with atrophic AMD in the macular area (geographic atrophy >250μm, involving the foveal center); or stable non-exudativeinactive neovascular AMD patients who have undergone treatment for wet AMD or have naturally converted to non-exudative AMD (referring to patients with fibrovascular scar formation, who are unresponsive to anti-VEGF treatment, and have no macular edema on OCT and/or no fluorescein leakage on FFA), with a scar diameter not exceeding 6 PD.
    Exclusion criteria
    • Edited(2)Presence of a scar, fibrosis, or atrophyfibrosis involving the fovea in the study eye, or a peripheral scar area greater than 6 PD, indicating severe irreversible visual loss.
    • Edited(3)Presence of pseudoexfoliation syndrome, central retinal vein occlusion, intraocular hemorrhage causing visual loss, rhegmatogenous retinal detachment, macular hole, or active choroidal neovascularization due to any cause in the study eye.
    • Edited(4)Presence of aAfferent pupillary block defect (APD) in the study eye.
    • Edited(5)Significant media opacity in the study eye (excluding lens opacities) that may interfere with visual function assessment or fundus examination.
    • ChangedBefore (10)The study eye has undergone the following intraocular surgeries or laser treatments within 3 months prior to screening, such as macular translocation, cataract surgery, glaucoma filtration surgery, verteporfin photodynamic therapy, transpupillary thermotherapy, foveal laser photocoagulation, vitrectomy, optic nerve decompression, or optic nerve sheath decompression.Now (10)The study eye has undergone any intraocular surgery within 3 months prior to screening.
    • Edited(11) Any eye has received anti-angiogenic drug treatmenttherapy (including any anti-VEGF drugs) within 3 months prior to screening (agents, e.g., Aflibercept [Eylea®], Ranibizumab [Lucentis®], Bevacizumab [Avastin®]) within 1 month prior to screening; or has undergone cataract surgery within 1 month prior to screening with unstable postoperative ocular conditions.
    • Edited(18)Patients with Presence of any uncontrollableuncontrolled systemic clinical issues (conditions, such as interstitial pneumonia, severe psychiatric, neurological, cardiovascular, or respiratory diseases, malignant tumors, Parkinson's disease, Alzheimer's disease, andor other severe systemic diseases)disorders.
    • Edited(21)Hemoglobin <100 g/L, platelets ≤100×10910\^9/L, neutrophil count <1.0×10910\^9/L, ALT/AST >1.5×upper limit of normal (ULN), creatinine >1.3 mg/dL.
    • Added(22)Subjects with any clinically significant finding in virological tests (HIV, HBV, HCV and TPPA).
    • Edited(2223)Patients deemed unsuitable for inclusion by the investigator, or other medical conditions that limit the subject's compliance, safety, or affect the results of the study trialtrial results.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Number of subjects with adverse eventsNow Incidence and Severity of Treatment-Related Adverse EventsTime frame: Two years following transplantation → Within 2 years after administration
    Secondary outcomes 1 edited, 1 time frame changed, 2 added, 1 description edited
    What changed in the outcomes
    • ChangedBefore Assessment of visual function changes-microperimetryNow Change-from-baseline in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) total scoreTime frame: From enrollment to the end of visiting at 2 years → From enrollment to the end of study at 12 months
    • Time frameAssessment of visual acuity using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart.From enrollment to the end of visiting at 2 years → From enrollment to the end of study at 12 months
    • DescriptionAssessment of visual acuity using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart.: how it is measured was reworded
    • Addedother outcomeChange-from-baseline in geographic atrophy lesion area measured by fundus autofluorescence (FAF) at 1 year post-treatmentTime frame: From enrollment to the end of study at 12 months
    • Addedother outcomeChange-from-baseline in macular and graft-site retinal structure assessed by optical coherence tomography (OCT) at 1 year post-treatmentTime frame: From enrollment to the end of study at 12 months
    Interventions Added Biological: hiPSC-RPEs; removed Biological: HiPSC-RPE cells·Drug: Erlotinib (150 mg daily)·Drug: Prednisone. Arms added: HiO-630 Dose-Escalation Cohorts; arms removed: HiPSC-RPE cells
    Title Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-Stagestage) AMD
    + 5 other changes: index terms, responsible party, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07418177
Collaborators
HELP Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Oct 14, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Songtao Yuan, M.D.
Contact
songtaoyuan@njmu.edu.cn
+86159-5108-8899
Songtao Yuan, M.D.
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion